Emerging Diseases News

A single dose of the Jynneos mpox vaccine reduces hospitalization risk and disease severity, a study found, although researchers emphasized that people at risk for the disease should complete the two-dose vaccine series.

Black and Hispanic patients with systemic lupus erythematous demonstrate more severe COVID-19 outcomes than white patients, according to data published in Arthritis Care & Research.

Consistently positive antinuclear antibody tests at 12 months following acute SARS-CoV-2 infection may predict long-term symptoms and inflammation, according to data published in the European Respiratory Journal.

Updated COVID-19 shots, including bivalent boosters, dominated vaccine news in 2022, but good news also came for vaccines against malaria, Ebola and cancer.

In 2022, the front page of Infectious Disease News mostly peered beyond COVID-19 to showcase triumphs and progress being made elsewhere in the field of infectious disease.

There was plenty of FDA news this year not related to COVID-19.

Starting Jan. 5, the United States will require inbound air travelers from China to present a negative COVID-19 test or documentation of recovery from COVID-19 when boarding their flight, the CDC announced.

People with MS who are being treated with rituximab are strongly encouraged to receive mRNA SARS-CoV-2 vaccines and booster doses more than 6 months after their last rituximab infusion, researchers reported in JAMA Network Open.

Mpox spread around the globe in 2022, popping up in 110 countries — including 103 that had not historically reported the disease, according to CDC tracking.

An asymptomatic SARS-CoV-2 patient admission testing program can provide clinically relevant data, even during periods of lower transmission in which testing can be limited to patients who are not fully vaccinated, a recent study showed.